When science stays the course, time becomes part of the treatment.

To provide the information your oncologist is not telling you or doesn't have the time to!
Explore the world of melanoma, a formidable form of skin cancer, through our dedicated “Melanoma” subcategory. Gain valuable insights into the causes, risk factors, and early detection of melanoma. Dive deep into the latest advancements in melanoma treatment options, including surgical interventions, immunotherapy, and targeted therapies. Whether you’re seeking information for prevention, diagnosis, or support, this subcategory is your trusted resource for comprehensive knowledge about melanoma. Together, we’ll navigate this journey toward melanoma awareness and effective management.

When science stays the course, time becomes part of the treatment.

Protecting vision, preserving the person — the promise of ocular-sparing oncology.

When innovation meets immune activation, new possibilities emerge for melanoma care.

Targeting PRAME with TCR-T cell therapy may mark a new era for immunotherapy in melanoma and beyond.

From early-stage to brain metastases, ASCO’s latest melanoma abstracts spotlight the growing power of targeted and immune-based therapies across disease stages.

ctDNA is helping us track what truly matters—real-time, personalized signals that guide smarter decisions in cancer care.

Stage IV melanoma used to be synonymous with a terminal diagnosis. For years, oncologists faced the grim reality of limited options and poor survival rates for their patients. However, the landscape has changed dramatically over the past decade. Breakthroughs in immunotherapy and clinical research have rewritten the narrative, offering hope to patients and their families. …

For patients with advanced melanoma who have exhausted standard treatment options, new therapies offer much-needed hope. On November 21, 2024, Replimune Group, Inc. announced that its breakthrough oncolytic immunotherapy, RP1 (vusolimogene oderparepvec), in combination with nivolumab, received Breakthrough Therapy Designation from the FDA. The FDA also accepted a Biologics License Application (BLA) for RP1 under …

When I meet new patients diagnosed with Stage IV metastatic melanoma, I often mention the name Jimmy Carter. It’s a name most people recognize, and his survival story is nothing short of remarkable—especially considering he will soon celebrate his 100th birthday. Like many of my patients, Carter was diagnosed with Stage IV melanoma, with metastatic …

Stage III melanoma means the cancer has spread beyond the original tumor to nearby areas but hasn’t reached distant parts of the body. The prognosis for Stage III melanoma varies depending on several factors, including the extent of lymph node involvement, the presence of in-transit or satellite lesions, and the patient’s overall health. Treatment for …